|1.||Kishnani, Priya S: 16 articles (11/2015 - 12/2010)|
|2.||Grabowski, Gregory A: 14 articles (12/2015 - 07/2010)|
|3.||Byrne, Barry J: 14 articles (09/2015 - 03/2002)|
|4.||Sun, Ying: 10 articles (12/2015 - 07/2010)|
|5.||Reuser, Arnold J J: 10 articles (03/2015 - 05/2004)|
|6.||Zhang, Wujuan: 9 articles (12/2015 - 01/2011)|
|7.||Setchell, Kenneth D R: 8 articles (12/2015 - 01/2011)|
|8.||Liou, Benjamin: 8 articles (12/2015 - 01/2011)|
|9.||Li, Songtao: 8 articles (11/2015 - 11/2010)|
|10.||van der Ploeg, Ans T: 8 articles (04/2015 - 12/2010)|
07/08/2013 - "The combination therapy of dipeptidyl-peptidase (DPP)-4 inhibitor and α-glucosidase inhibitors (α-GIs) is highly effective in suppressing postprandial hyperglycemia. "
11/09/2012 - "Of all available anti-diabetic drugs, α-glucosidase inhibitors seem to be the most effective in reducing post-prandial hyperglycemia. "
12/24/2015 - "The study is also aimed at describing structural activity relationship, type of α-glucosidase inhibition and in-vivo potential to regulate post prandial hyperglycemia in Wistar rats. "
01/01/2015 - "In this study, we aimed to investigate whether treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4I) or an α-glucosidase inhibitor (α-GI), either of which suppresses postprandial hyperglycemia, reduces the expression of CVD risk factors in an IGT animal model. "
06/01/2015 - "Daraesoon effectively suppressed postprandial hyperglycemia via the inhibition of α-glucosidase in STZ-induced diabetic rats. "
|2.||Glycogen Storage Disease Type II (Pompe's Disease)
05/01/2011 - "Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots."
12/01/2010 - "Treatment of infantile Pompe disease with recombinant human acid α-glucosidase has shown substantial improvement in survival, and in cardiac, motor and respiratory functions. "
05/01/2004 - "We tested the long-term safety and efficacy of recombinant human -glucosidase (rhAGLU) from rabbit milk for the treatment of the lysosomal storage disorder Pompe disease. "
08/01/1992 - "Our results showed that alpha-D-glucosidase did exist in the skin fibroblasts of all seven Pompe's disease patients by RIP and in the hepatic cells by immunohistological study. "
08/01/1986 - "Study of alpha-D-glucosidase activity in patients with Pompe's disease."
04/15/1986 - "The results of these first clinical pharmacological studies with two new glucosidase inhibitors justify studies on patients with diabetes mellitus."
01/01/2016 - "α-Glucosidase is a therapeutic target for diabetes mellitus, and α-glucosidase inhibitors play a vital role in the treatments for the disease. "
06/01/2015 - "The results demonstrate that ultrafiltration, liquid chromatography and mass spectrometry combined with high-speed counter-current chromatography might provide not only a powerful tool for screening and isolating α-glucosidase inhibitors in complex samples but also a useful platform for discovering bioactive compounds for the prevention and treatment of diabetes mellitus. "
01/01/2014 - "A promising approach for treating diabetes mellitus (DM) is to decrease postprandial hyperglycaemia by suppressing carbohydrate digestion using α-glucosidase inhibitors. "
11/01/2013 - "The inhibition of the α-glucosidase enzyme plays an important role in the treatment of diabetes mellitus. "
|4.||Type 2 Diabetes Mellitus (MODY)
01/01/2016 - "Therefore, our present in vitro and in vivo studies demonstrated that FvF could be a promising α-glucosidase inhibitor for the treatment of type 2 diabetes mellitus. "
01/01/2015 - "Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review."
11/01/2014 - "Naturally existing -α -glucosidase inhibitors from traditional herbal medicines have attracted considerable interest to treat type 2 diabetes mellitus (T2DM). "
06/01/2014 - "These results suggest that Ca(2+) could act as a potent inhibitor of α-glucosidase for the treatment of type 2 diabetes mellitus. "
06/01/2014 - "Understanding the mechanism of inhibition of α-glucosidase (EC 18.104.22.168) is clinically important because of the involvement of this enzyme in type 2 diabetes mellitus. "
|5.||Gaucher Disease (Gaucher's Disease)
08/01/2013 - "In addition, since these mice produce only human enzyme, they are particularly relevant for the study of pharmacological chaperones that are specifically targeted to human acid β-glucosidase and the common mutations underlying Gaucher disease."
10/01/2011 - "Recently, two studies were published that examined the structure of the acid-β-glucosidase N370S mutant, the most common mutant that causes Gaucher disease. "
09/21/2015 - "Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease."
05/01/2015 - "Among these, the Gaucher disease (GD), an heterogeneous lysosomal storage determined by hereditary enzyme deficiency of β-glucosidase. "
05/01/2015 - "By proof-of-principle experiments, we have previously demonstrated a reversal of symptoms in a murine disease model of type 1 Gaucher disease, using gammaretroviral vectors harboring strong viral promoters to drive glucosidase β-acid (GBA) gene expression. "
|6.||Blood Glucose (Blood Sugar)
|7.||1-Deoxynojirimycin (1 Deoxynojirimycin)
|10.||human GAA protein (Myozyme)
|1.||Enzyme Replacement Therapy
|2.||Mechanical Ventilators (Ventilator)
|4.||Chinese Traditional Medicine (Traditional Chinese Medicine)